S Gill1, D Hao2, H Hirte3, A Campbell4, B Colwell5. 1. BC Cancer and University of British Columbia, Vancouver, BC. 2. Tom Baker Cancer Centre and Cumming School of Medicine, University of Calgary, Calgary, AB. 3. Juravinski Cancer Centre, Hamilton, ON. 4. Canadian Association of Medical Oncologists, Ottawa, ON. 5. Dalhousie University, Halifax, NS.
Abstract
Background: The covid-19 pandemic has presented unprecedented professional and personal challenges for the oncology community. Under the auspices of the Canadian Association of Medical Oncologists, we conducted an online national survey to better understand the impact of the pandemic on the medical oncology community in Canada. Methods: An English-language multiple-choice survey, including questions about demographics, covid-19 risk, use of personal protective equipment (ppe), personal challenges, and chemotherapy management was distributed to Canadian medical oncologists. The survey was open from 30 March to 4 April 2020, and attracted 159 responses. Results: More than 70% of medical oncologists expressed moderate-to-extreme concern about personally contracting covid-19 and about family members or patients (or both) contracting covid-19 from them. Despite that high level of concern, considerable variability in the use of ppe in direct cancer care was reported at the time of this survey, with 33% of respondents indicating no routine ppe use at their institutions and 69% indicating uncertainty about access to adequate ppe. Of the respondents, 54% were experiencing feelings of nervousness or anxiety on most days, and 52% were having feelings of depression or hopelessness on at least some days. Concern about aging parents or family and individual wellness represented the top personal challenges identified. The management of cancer patients has been affected, with adoption of telemedicine reported by 82% of respondents, and cessation of clinical trial accrual reported by 54%. The 3 factors deemed most important for treatment decision-making were■ cancer prognosis and anticipated benefit from treatment,■ risk of treatment toxicity during scarce health care access, and■ patient risk of contracting covid-19. Conclusions: This report describes the results of the first national survey assessing the impact of the covid-19 on Canadian medical oncologists and how they deliver systemic anticancer therapies. We hope that these data will provide a framework to address the challenges identified. 2020 Multimed Inc.
Background: The covid-19 pandemic has presented unprecedented professional and personal challenges for the oncology community. Under the auspices of the Canadian Association of Medical Oncologists, we conducted an online national survey to better understand the impact of the pandemic on the medical oncology community in Canada. Methods: An English-language multiple-choice survey, including questions about demographics, covid-19 risk, use of personal protective equipment (ppe), personal challenges, and chemotherapy management was distributed to Canadian medical oncologists. The survey was open from 30 March to 4 April 2020, and attracted 159 responses. Results: More than 70% of medical oncologists expressed moderate-to-extreme concern about personally contracting covid-19 and about family members or patients (or both) contracting covid-19 from them. Despite that high level of concern, considerable variability in the use of ppe in direct cancer care was reported at the time of this survey, with 33% of respondents indicating no routine ppe use at their institutions and 69% indicating uncertainty about access to adequate ppe. Of the respondents, 54% were experiencing feelings of nervousness or anxiety on most days, and 52% were having feelings of depression or hopelessness on at least some days. Concern about aging parents or family and individual wellness represented the top personal challenges identified. The management of cancerpatients has been affected, with adoption of telemedicine reported by 82% of respondents, and cessation of clinical trial accrual reported by 54%. The 3 factors deemed most important for treatment decision-making were■ cancer prognosis and anticipated benefit from treatment,■ risk of treatment toxicity during scarce health care access, and■ patient risk of contracting covid-19. Conclusions: This report describes the results of the first national survey assessing the impact of the covid-19 on Canadian medical oncologists and how they deliver systemic anticancer therapies. We hope that these data will provide a framework to address the challenges identified. 2020 Multimed Inc.
Entities:
Keywords:
camo; covid-19; medical oncology; surveys
Authors: Jordan M Alpert; Gemme Campbell-Salome; Cayle Gao; Merry Jennifer Markham; Martina Murphy; Christopher A Harle; Samantha R Paige; Till Krenz; Carma L Bylund Journal: Telemed J E Health Date: 2021-11-11 Impact factor: 5.033
Authors: Julie Tsu-Yu Wu; Daniel H Kwon; Michael J Glover; Solomon Henry; Douglas Wood; Daniel L Rubin; Vadim S Koshkin; Lidia Schapira; Sumit A Shah Journal: JCO Oncol Pract Date: 2020-12-17
Authors: Omid Salehi; Sylvia V Alarcon; Eduardo A Vega; Onur C Kutlu; Olga Kozyreva; Jennifer A Chan; Vera Kazakova; Dominique Harz; Claudius Conrad Journal: J Gastrointest Surg Date: 2021-05-23 Impact factor: 3.267
Authors: Kirsten M Fiest; Jeanna Parsons Leigh; Karla D Krewulak; Kara M Plotnikoff; Laryssa G Kemp; Joshua Ng-Kamstra; Henry T Stelfox Journal: BMC Psychiatry Date: 2021-02-10 Impact factor: 3.630
Authors: Maciej M Mrugala; Quinn T Ostrom; Shelley M Pressley; Jennie W Taylor; Alissa A Thomas; Jeffrey S Wefel; Scott L Coven; Alvina A Acquaye; Chas Haynes; Sameer Agnihotri; Michael Lim; Katherine B Peters; Erik P Sulman; Joanne T Salcido; Nicholas A Butowski; Shawn Hervey-Jumper; Alireza Mansouri; Kathy R Oliver; Alyx B Porter; Farshad Nassiri; David Schiff; Erin M Dunbar; Monika E Hegi; Terri S Armstrong; Martin J van den Bent; Susan M Chang; Gelareh Zadeh; Milan G Chheda Journal: Neurooncol Adv Date: 2021-02-20
Authors: F Panzuto; M Maccauro; D Campana; A Faggiano; S Massironi; S Pusceddu; F Spada; D Ferone; R Modica; C M Grana; P Ferolla; M Rinzivillo; G Badalamenti; M C Zatelli; F Gelsomino; E De Carlo; M Bartolomei; M P Brizzi; S Cingarlini; A Versari; G Fanciulli; E Arvat; E Merola; M Cives; S Tafuto; S Baldari; M Falconi Journal: J Endocrinol Invest Date: 2020-08-16 Impact factor: 4.256